| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Hepatocellular | 26 | 2025 | 1005 | 2.230 |
Why?
|
| Liver Neoplasms | 27 | 2025 | 1398 | 1.970 |
Why?
|
| Liver Cirrhosis | 17 | 2025 | 909 | 1.450 |
Why?
|
| Veterans | 37 | 2026 | 1792 | 1.340 |
Why?
|
| alpha-Fetoproteins | 10 | 2020 | 138 | 1.290 |
Why?
|
| Hepatitis C, Chronic | 11 | 2025 | 366 | 1.260 |
Why?
|
| Hepatitis C | 13 | 2018 | 389 | 1.120 |
Why?
|
| Renal Insufficiency, Chronic | 7 | 2023 | 851 | 0.960 |
Why?
|
| Antiviral Agents | 8 | 2025 | 811 | 0.940 |
Why?
|
| Interferons | 1 | 2025 | 136 | 0.830 |
Why?
|
| United States Department of Veterans Affairs | 19 | 2026 | 718 | 0.790 |
Why?
|
| Barrett Esophagus | 10 | 2013 | 361 | 0.740 |
Why?
|
| United States | 57 | 2026 | 11831 | 0.730 |
Why?
|
| Algorithms | 11 | 2020 | 1677 | 0.720 |
Why?
|
| Middle Aged | 88 | 2026 | 28494 | 0.710 |
Why?
|
| HIV Infections | 13 | 2025 | 2015 | 0.700 |
Why?
|
| Subacute Care | 2 | 2018 | 8 | 0.670 |
Why?
|
| Creatinine | 1 | 2021 | 397 | 0.620 |
Why?
|
| Glomerular Filtration Rate | 2 | 2021 | 567 | 0.590 |
Why?
|
| Aged | 65 | 2026 | 20956 | 0.590 |
Why?
|
| Quality Improvement | 5 | 2026 | 704 | 0.580 |
Why?
|
| Colorectal Neoplasms | 5 | 2017 | 635 | 0.560 |
Why?
|
| Hepatitis B, Chronic | 5 | 2022 | 89 | 0.550 |
Why?
|
| International Classification of Diseases | 6 | 2018 | 97 | 0.530 |
Why?
|
| Colorectal Surgery | 1 | 2017 | 10 | 0.520 |
Why?
|
| Gastroesophageal Reflux | 9 | 2013 | 333 | 0.520 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2022 | 755 | 0.510 |
Why?
|
| Proton Pump Inhibitors | 6 | 2017 | 277 | 0.500 |
Why?
|
| Male | 92 | 2026 | 64669 | 0.500 |
Why?
|
| Oropharyngeal Neoplasms | 4 | 2022 | 265 | 0.490 |
Why?
|
| Veterans Health | 3 | 2025 | 171 | 0.480 |
Why?
|
| Cohort Studies | 29 | 2025 | 5088 | 0.470 |
Why?
|
| Female | 87 | 2026 | 70618 | 0.450 |
Why?
|
| Surgical Procedures, Operative | 3 | 2026 | 226 | 0.450 |
Why?
|
| Humans | 116 | 2026 | 130749 | 0.450 |
Why?
|
| Decision Support Techniques | 3 | 2015 | 297 | 0.430 |
Why?
|
| Histamine H2 Antagonists | 2 | 2017 | 49 | 0.420 |
Why?
|
| Risk Factors | 32 | 2025 | 11001 | 0.410 |
Why?
|
| Quality Indicators, Health Care | 3 | 2024 | 234 | 0.410 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 5 | 2021 | 407 | 0.390 |
Why?
|
| Head and Neck Neoplasms | 3 | 2025 | 636 | 0.380 |
Why?
|
| Retrospective Studies | 42 | 2025 | 17672 | 0.380 |
Why?
|
| Hepatitis B | 3 | 2021 | 173 | 0.370 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 6 | 2013 | 300 | 0.350 |
Why?
|
| Serum | 1 | 2011 | 43 | 0.350 |
Why?
|
| Hospitals, Veterans | 5 | 2021 | 345 | 0.350 |
Why?
|
| Anus Neoplasms | 3 | 2021 | 43 | 0.350 |
Why?
|
| Anti-Ulcer Agents | 3 | 2009 | 114 | 0.350 |
Why?
|
| Colitis, Ulcerative | 5 | 2017 | 216 | 0.340 |
Why?
|
| Inflammatory Bowel Diseases | 5 | 2018 | 326 | 0.340 |
Why?
|
| Esophageal Neoplasms | 5 | 2019 | 396 | 0.330 |
Why?
|
| Adult | 49 | 2025 | 31266 | 0.330 |
Why?
|
| Alanine Transaminase | 3 | 2018 | 156 | 0.330 |
Why?
|
| Azetidines | 2 | 2021 | 63 | 0.320 |
Why?
|
| Hospital Mortality | 6 | 2023 | 1073 | 0.320 |
Why?
|
| Aged, 80 and over | 19 | 2021 | 6783 | 0.300 |
Why?
|
| Hepatitis B virus | 4 | 2022 | 137 | 0.290 |
Why?
|
| Risk Assessment | 11 | 2025 | 3715 | 0.290 |
Why?
|
| Gulf War | 2 | 2025 | 10 | 0.280 |
Why?
|
| Protease Inhibitors | 2 | 2021 | 94 | 0.280 |
Why?
|
| Sulfonamides | 2 | 2021 | 296 | 0.280 |
Why?
|
| Hospitals | 4 | 2024 | 436 | 0.280 |
Why?
|
| Incidence | 16 | 2022 | 3349 | 0.270 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2023 | 217 | 0.270 |
Why?
|
| Case-Control Studies | 18 | 2021 | 3418 | 0.260 |
Why?
|
| Hospitalization | 6 | 2021 | 1934 | 0.260 |
Why?
|
| Crohn Disease | 4 | 2017 | 291 | 0.260 |
Why?
|
| Logistic Models | 12 | 2021 | 1823 | 0.260 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 2023 | 139 | 0.250 |
Why?
|
| Population Surveillance | 4 | 2021 | 395 | 0.250 |
Why?
|
| Age Factors | 8 | 2019 | 2847 | 0.250 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2010 | 771 | 0.250 |
Why?
|
| Patient Compliance | 1 | 2009 | 468 | 0.240 |
Why?
|
| Hepacivirus | 3 | 2013 | 273 | 0.230 |
Why?
|
| Mass Screening | 6 | 2018 | 807 | 0.230 |
Why?
|
| Prognosis | 11 | 2026 | 4933 | 0.230 |
Why?
|
| Cardiovascular Diseases | 5 | 2023 | 2099 | 0.230 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2025 | 33 | 0.220 |
Why?
|
| Atherosclerosis | 2 | 2025 | 949 | 0.220 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2018 | 641 | 0.220 |
Why?
|
| Postoperative Complications | 4 | 2024 | 3113 | 0.210 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2026 | 148 | 0.210 |
Why?
|
| Occupational Exposure | 1 | 2025 | 137 | 0.210 |
Why?
|
| Electronic Health Records | 5 | 2026 | 811 | 0.210 |
Why?
|
| Monocytes | 1 | 2026 | 335 | 0.200 |
Why?
|
| Proportional Hazards Models | 8 | 2026 | 1408 | 0.200 |
Why?
|
| Persian Gulf Syndrome | 1 | 2023 | 16 | 0.200 |
Why?
|
| Natural Language Processing | 2 | 2016 | 78 | 0.200 |
Why?
|
| Purines | 2 | 2021 | 115 | 0.200 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2019 | 133 | 0.200 |
Why?
|
| Angioedema | 1 | 2023 | 21 | 0.190 |
Why?
|
| Databases, Factual | 4 | 2020 | 1223 | 0.190 |
Why?
|
| Body Mass Index | 3 | 2018 | 1685 | 0.190 |
Why?
|
| Quality Assurance, Health Care | 2 | 2021 | 210 | 0.190 |
Why?
|
| Survival Analysis | 6 | 2017 | 1512 | 0.180 |
Why?
|
| Hyperlipidemias | 1 | 2023 | 189 | 0.180 |
Why?
|
| HIV | 2 | 2020 | 177 | 0.180 |
Why?
|
| Pancreatic Neoplasms | 2 | 2018 | 743 | 0.180 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2021 | 36 | 0.170 |
Why?
|
| Perioperative Period | 1 | 2021 | 51 | 0.170 |
Why?
|
| Pyrazoles | 2 | 2021 | 356 | 0.170 |
Why?
|
| Prevalence | 12 | 2021 | 2683 | 0.170 |
Why?
|
| Janus Kinases | 1 | 2021 | 34 | 0.170 |
Why?
|
| Ovarian Neoplasms | 1 | 2025 | 453 | 0.170 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 119 | 0.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 266 | 0.160 |
Why?
|
| Predictive Value of Tests | 7 | 2018 | 2307 | 0.160 |
Why?
|
| Reproducibility of Results | 7 | 2018 | 2937 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2025 | 814 | 0.160 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 5230 | 0.160 |
Why?
|
| Registries | 7 | 2019 | 1599 | 0.150 |
Why?
|
| Anti-HIV Agents | 1 | 2022 | 347 | 0.150 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2020 | 748 | 0.150 |
Why?
|
| Cross-Sectional Studies | 11 | 2026 | 3823 | 0.140 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2021 | 141 | 0.140 |
Why?
|
| Alcohol Drinking | 3 | 2019 | 346 | 0.140 |
Why?
|
| Evidence-Based Medicine | 3 | 2016 | 643 | 0.140 |
Why?
|
| Odds Ratio | 6 | 2021 | 1230 | 0.140 |
Why?
|
| Length of Stay | 3 | 2021 | 1398 | 0.140 |
Why?
|
| Gout | 1 | 2021 | 172 | 0.140 |
Why?
|
| Platelet Count | 2 | 2018 | 139 | 0.140 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2018 | 32 | 0.140 |
Why?
|
| Outpatients | 2 | 2013 | 266 | 0.140 |
Why?
|
| Time Factors | 6 | 2025 | 6240 | 0.140 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 564 | 0.140 |
Why?
|
| Diet, Fat-Restricted | 1 | 2018 | 37 | 0.140 |
Why?
|
| Sarcoma, Kaposi | 1 | 2019 | 128 | 0.140 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 384 | 0.140 |
Why?
|
| Virus Activation | 1 | 2018 | 86 | 0.130 |
Why?
|
| Colonoscopy | 2 | 2012 | 246 | 0.130 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 895 | 0.130 |
Why?
|
| Adipokines | 1 | 2018 | 121 | 0.130 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2020 | 677 | 0.130 |
Why?
|
| Deglutition Disorders | 1 | 2019 | 138 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 124 | 0.130 |
Why?
|
| Treatment Outcome | 10 | 2022 | 12908 | 0.130 |
Why?
|
| Gastric Acid | 1 | 2017 | 55 | 0.130 |
Why?
|
| Hypertension | 2 | 2023 | 1356 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 285 | 0.130 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2017 | 86 | 0.120 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2020 | 228 | 0.120 |
Why?
|
| Gastrointestinal Agents | 1 | 2017 | 63 | 0.120 |
Why?
|
| Endoscopy, Gastrointestinal | 4 | 2013 | 231 | 0.120 |
Why?
|
| Drug Prescriptions | 2 | 2010 | 230 | 0.120 |
Why?
|
| Sensitivity and Specificity | 7 | 2018 | 2126 | 0.120 |
Why?
|
| Liver | 2 | 2021 | 1802 | 0.120 |
Why?
|
| Tuberculin Test | 1 | 2017 | 120 | 0.120 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 312 | 0.120 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2020 | 317 | 0.120 |
Why?
|
| Survival Rate | 5 | 2021 | 2146 | 0.120 |
Why?
|
| Needs Assessment | 1 | 2017 | 176 | 0.120 |
Why?
|
| Latent Tuberculosis | 1 | 2017 | 76 | 0.120 |
Why?
|
| Adenocarcinoma | 3 | 2019 | 987 | 0.120 |
Why?
|
| Smoking | 3 | 2019 | 926 | 0.120 |
Why?
|
| Liver Function Tests | 2 | 2014 | 97 | 0.120 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 60 | 0.120 |
Why?
|
| Activities of Daily Living | 2 | 2016 | 380 | 0.120 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 301 | 0.120 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 335 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 618 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 364 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 375 | 0.110 |
Why?
|
| Recovery of Function | 1 | 2017 | 443 | 0.110 |
Why?
|
| Postoperative Care | 1 | 2017 | 297 | 0.110 |
Why?
|
| ROC Curve | 2 | 2021 | 615 | 0.110 |
Why?
|
| Mortality | 1 | 2016 | 260 | 0.110 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2016 | 140 | 0.110 |
Why?
|
| Stomach | 2 | 2007 | 271 | 0.110 |
Why?
|
| Medical History Taking | 2 | 2016 | 109 | 0.110 |
Why?
|
| Multivariate Analysis | 5 | 2018 | 1387 | 0.110 |
Why?
|
| Databases as Topic | 2 | 2011 | 74 | 0.110 |
Why?
|
| Intensive Care, Neonatal | 1 | 2014 | 56 | 0.100 |
Why?
|
| Data Collection | 4 | 2023 | 366 | 0.100 |
Why?
|
| Risk Adjustment | 2 | 2021 | 57 | 0.100 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2005 | 94 | 0.100 |
Why?
|
| Viremia | 2 | 2011 | 131 | 0.100 |
Why?
|
| Ultrasonography | 3 | 2018 | 974 | 0.100 |
Why?
|
| Stomach Neoplasms | 1 | 2019 | 579 | 0.100 |
Why?
|
| Hepatitis | 1 | 2013 | 57 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 497 | 0.100 |
Why?
|
| Parkinson Disease | 1 | 2020 | 722 | 0.100 |
Why?
|
| Fructose | 1 | 2013 | 61 | 0.100 |
Why?
|
| Obesity, Abdominal | 1 | 2013 | 41 | 0.100 |
Why?
|
| Waist-Hip Ratio | 1 | 2012 | 54 | 0.100 |
Why?
|
| Subcutaneous Fat | 1 | 2013 | 34 | 0.100 |
Why?
|
| Endoscopy | 2 | 2012 | 272 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1158 | 0.090 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2014 | 169 | 0.090 |
Why?
|
| Dietary Carbohydrates | 1 | 2013 | 108 | 0.090 |
Why?
|
| Intra-Abdominal Fat | 1 | 2013 | 65 | 0.090 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 72 | 0.090 |
Why?
|
| Early Detection of Cancer | 4 | 2020 | 418 | 0.090 |
Why?
|
| Renin-Angiotensin System | 2 | 2023 | 104 | 0.090 |
Why?
|
| Fibrinolytic Agents | 1 | 2013 | 199 | 0.090 |
Why?
|
| Immunologic Factors | 1 | 2013 | 189 | 0.090 |
Why?
|
| Current Procedural Terminology | 1 | 2011 | 5 | 0.090 |
Why?
|
| Health Services Administration | 1 | 2011 | 8 | 0.090 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 1609 | 0.090 |
Why?
|
| Esophagus | 2 | 2011 | 236 | 0.090 |
Why?
|
| Blood Transfusion | 1 | 2013 | 291 | 0.090 |
Why?
|
| Spironolactone | 1 | 2011 | 20 | 0.090 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2013 | 231 | 0.090 |
Why?
|
| Coinfection | 1 | 2013 | 188 | 0.090 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2008 | 257 | 0.090 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2013 | 274 | 0.090 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2014 | 341 | 0.090 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2011 | 44 | 0.080 |
Why?
|
| Cause of Death | 3 | 2016 | 512 | 0.080 |
Why?
|
| Biomarkers | 4 | 2018 | 3400 | 0.080 |
Why?
|
| Likelihood Functions | 1 | 2010 | 117 | 0.080 |
Why?
|
| Calibration | 1 | 2010 | 92 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2021 | 151 | 0.080 |
Why?
|
| Health Facilities | 1 | 2010 | 67 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 3 | 2012 | 1299 | 0.080 |
Why?
|
| Diphosphonates | 1 | 2010 | 41 | 0.080 |
Why?
|
| Risk | 3 | 2020 | 736 | 0.080 |
Why?
|
| Patient-Centered Care | 1 | 2012 | 228 | 0.080 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2010 | 66 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2104 | 0.080 |
Why?
|
| Managed Care Programs | 1 | 2009 | 56 | 0.070 |
Why?
|
| Family Health | 1 | 2010 | 243 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2013 | 559 | 0.070 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2017 | 834 | 0.070 |
Why?
|
| Guideline Adherence | 2 | 2011 | 391 | 0.070 |
Why?
|
| Health Services Research | 1 | 2010 | 179 | 0.070 |
Why?
|
| Prospective Studies | 5 | 2021 | 6494 | 0.070 |
Why?
|
| Anticoagulants | 1 | 2013 | 600 | 0.070 |
Why?
|
| Disease Progression | 3 | 2026 | 2202 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2025 | 1307 | 0.070 |
Why?
|
| Stroke Volume | 1 | 2011 | 532 | 0.070 |
Why?
|
| Inpatients | 1 | 2013 | 546 | 0.070 |
Why?
|
| Heart Failure | 3 | 2016 | 2317 | 0.070 |
Why?
|
| Endoscopy, Digestive System | 1 | 2009 | 153 | 0.070 |
Why?
|
| Severity of Illness Index | 6 | 2016 | 3062 | 0.070 |
Why?
|
| Sex Factors | 3 | 2019 | 1341 | 0.070 |
Why?
|
| Motor Activity | 1 | 2010 | 499 | 0.070 |
Why?
|
| Cardia | 1 | 2007 | 26 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2013 | 978 | 0.060 |
Why?
|
| Comorbidity | 3 | 2020 | 1594 | 0.060 |
Why?
|
| Patient Selection | 1 | 2010 | 722 | 0.060 |
Why?
|
| Military Personnel | 1 | 2009 | 215 | 0.060 |
Why?
|
| Adolescent | 9 | 2023 | 20832 | 0.060 |
Why?
|
| Intestinal Mucosa | 1 | 2011 | 768 | 0.060 |
Why?
|
| Peptic Ulcer | 2 | 2006 | 149 | 0.060 |
Why?
|
| Diagnostic Errors | 1 | 2010 | 342 | 0.060 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2006 | 130 | 0.060 |
Why?
|
| Medicare | 3 | 2018 | 439 | 0.060 |
Why?
|
| Esophagoscopy | 1 | 2006 | 177 | 0.060 |
Why?
|
| Leukocyte Count | 1 | 2026 | 248 | 0.060 |
Why?
|
| Platinum | 1 | 2025 | 13 | 0.060 |
Why?
|
| Respiration Disorders | 1 | 2005 | 31 | 0.060 |
Why?
|
| Infliximab | 2 | 2017 | 64 | 0.060 |
Why?
|
| Feeding Behavior | 1 | 2010 | 717 | 0.060 |
Why?
|
| Smoke | 1 | 2025 | 81 | 0.050 |
Why?
|
| Fundoplication | 1 | 2005 | 70 | 0.050 |
Why?
|
| Fournier Gangrene | 1 | 2004 | 2 | 0.050 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2016 | 650 | 0.050 |
Why?
|
| Cytokines | 2 | 2021 | 1339 | 0.050 |
Why?
|
| Famous Persons | 1 | 2004 | 14 | 0.050 |
Why?
|
| Obesity | 4 | 2022 | 2389 | 0.050 |
Why?
|
| Gastrointestinal Diseases | 1 | 2008 | 340 | 0.050 |
Why?
|
| Psychotic Disorders | 1 | 2005 | 154 | 0.050 |
Why?
|
| Neoplasms | 1 | 2018 | 2956 | 0.050 |
Why?
|
| Texas | 3 | 2021 | 3633 | 0.050 |
Why?
|
| Patient Outcome Assessment | 1 | 2023 | 90 | 0.050 |
Why?
|
| Morbidity | 1 | 2024 | 261 | 0.050 |
Why?
|
| Age Distribution | 3 | 2013 | 426 | 0.050 |
Why?
|
| Bipolar Disorder | 1 | 2005 | 309 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 893 | 0.050 |
Why?
|
| Musculoskeletal Diseases | 1 | 2003 | 56 | 0.050 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2022 | 32 | 0.050 |
Why?
|
| Drug Costs | 1 | 2002 | 63 | 0.050 |
Why?
|
| Tenofovir | 1 | 2022 | 26 | 0.050 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 4037 | 0.050 |
Why?
|
| Young Adult | 4 | 2021 | 10021 | 0.040 |
Why?
|
| Guanine | 1 | 2022 | 65 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2013 | 270 | 0.040 |
Why?
|
| ABO Blood-Group System | 1 | 2021 | 61 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2003 | 351 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2021 | 122 | 0.040 |
Why?
|
| Demography | 2 | 2016 | 239 | 0.040 |
Why?
|
| Papillomaviridae | 1 | 2022 | 178 | 0.040 |
Why?
|
| Spain | 1 | 2021 | 59 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2021 | 321 | 0.040 |
Why?
|
| Italy | 1 | 2021 | 111 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2021 | 137 | 0.040 |
Why?
|
| Virus Internalization | 1 | 2021 | 58 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2023 | 421 | 0.040 |
Why?
|
| Platelet Activation | 1 | 2021 | 67 | 0.040 |
Why?
|
| Intraocular Pressure | 1 | 2021 | 133 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 350 | 0.040 |
Why?
|
| Ferritins | 1 | 2021 | 108 | 0.040 |
Why?
|
| Drug Repositioning | 1 | 2020 | 32 | 0.040 |
Why?
|
| Spheroids, Cellular | 1 | 2020 | 59 | 0.040 |
Why?
|
| Pain | 1 | 2003 | 432 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2013 | 1164 | 0.040 |
Why?
|
| Hernia, Hiatal | 2 | 2012 | 58 | 0.040 |
Why?
|
| Weight Gain | 1 | 2022 | 382 | 0.040 |
Why?
|
| Models, Statistical | 2 | 2013 | 485 | 0.040 |
Why?
|
| SEER Program | 1 | 2020 | 214 | 0.040 |
Why?
|
| Osteoarthritis, Knee | 1 | 2003 | 276 | 0.040 |
Why?
|
| Geography | 1 | 2019 | 117 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 1236 | 0.040 |
Why?
|
| Anxiety Disorders | 1 | 2005 | 731 | 0.040 |
Why?
|
| Leukocytes | 1 | 2020 | 207 | 0.040 |
Why?
|
| Recurrence | 2 | 2017 | 1478 | 0.040 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2018 | 40 | 0.040 |
Why?
|
| Gastrostomy | 1 | 2019 | 88 | 0.040 |
Why?
|
| Skilled Nursing Facilities | 1 | 2018 | 7 | 0.040 |
Why?
|
| Plasminogen Inactivators | 1 | 2018 | 5 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 503 | 0.040 |
Why?
|
| Body Weight | 1 | 2022 | 989 | 0.030 |
Why?
|
| Anxiety | 1 | 2005 | 1009 | 0.030 |
Why?
|
| Edible Grain | 1 | 2018 | 43 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 60 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2018 | 113 | 0.030 |
Why?
|
| Protective Factors | 1 | 2018 | 93 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2019 | 768 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 153 | 0.030 |
Why?
|
| Adiponectin | 1 | 2018 | 124 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 587 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2025 | 3698 | 0.030 |
Why?
|
| Postmenopause | 1 | 2018 | 148 | 0.030 |
Why?
|
| Certolizumab Pegol | 1 | 2017 | 8 | 0.030 |
Why?
|
| Critical Illness | 1 | 2021 | 615 | 0.030 |
Why?
|
| Adalimumab | 1 | 2017 | 22 | 0.030 |
Why?
|
| Patient Transfer | 1 | 2018 | 111 | 0.030 |
Why?
|
| Helicobacter pylori | 2 | 2019 | 1358 | 0.030 |
Why?
|
| Leptin | 1 | 2018 | 217 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2018 | 309 | 0.030 |
Why?
|
| Fruit | 1 | 2018 | 235 | 0.030 |
Why?
|
| Lipids | 1 | 2020 | 563 | 0.030 |
Why?
|
| Metaplasia | 2 | 2007 | 216 | 0.030 |
Why?
|
| Sustained Virologic Response | 1 | 2016 | 47 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2004 | 942 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2018 | 256 | 0.030 |
Why?
|
| Patient Safety | 1 | 2021 | 444 | 0.030 |
Why?
|
| Depression | 1 | 2005 | 1327 | 0.030 |
Why?
|
| Biopsy | 2 | 2011 | 1241 | 0.030 |
Why?
|
| Vegetables | 1 | 2018 | 271 | 0.030 |
Why?
|
| Esophagitis | 2 | 2006 | 39 | 0.030 |
Why?
|
| Reference Values | 2 | 2007 | 680 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2002 | 895 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 384 | 0.030 |
Why?
|
| End Stage Liver Disease | 1 | 2016 | 191 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2018 | 511 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 1842 | 0.030 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2012 | 12 | 0.020 |
Why?
|
| Gastritis | 2 | 2007 | 370 | 0.020 |
Why?
|
| Diet | 1 | 2019 | 1116 | 0.020 |
Why?
|
| Metabolic Syndrome | 1 | 2015 | 366 | 0.020 |
Why?
|
| Age of Onset | 1 | 2013 | 597 | 0.020 |
Why?
|
| Ribavirin | 1 | 2011 | 86 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 95 | 0.020 |
Why?
|
| Coffee | 1 | 2010 | 30 | 0.020 |
Why?
|
| Colon | 1 | 2012 | 356 | 0.020 |
Why?
|
| Collagen | 1 | 2011 | 283 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2011 | 240 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2014 | 8565 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 877 | 0.020 |
Why?
|
| Trachea | 1 | 2011 | 207 | 0.020 |
Why?
|
| Helicobacter Infections | 2 | 2013 | 1302 | 0.020 |
Why?
|
| Child | 4 | 2013 | 26213 | 0.020 |
Why?
|
| Fatty Liver | 1 | 2010 | 222 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2012 | 697 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2010 | 509 | 0.020 |
Why?
|
| Pyloric Antrum | 1 | 2007 | 63 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2011 | 1625 | 0.020 |
Why?
|
| Contraceptives, Oral | 1 | 2007 | 40 | 0.020 |
Why?
|
| Barium Sulfate | 1 | 2006 | 13 | 0.020 |
Why?
|
| Sigmoidoscopy | 1 | 2006 | 11 | 0.020 |
Why?
|
| Intestinal Polyps | 1 | 2006 | 30 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3869 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 673 | 0.020 |
Why?
|
| Occult Blood | 1 | 2006 | 32 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2006 | 37 | 0.020 |
Why?
|
| Enema | 1 | 2006 | 47 | 0.020 |
Why?
|
| Body Fat Distribution | 1 | 2006 | 32 | 0.020 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 47 | 0.020 |
Why?
|
| Manometry | 1 | 2006 | 73 | 0.020 |
Why?
|
| Prejudice | 1 | 2006 | 40 | 0.020 |
Why?
|
| Pressure | 1 | 2006 | 122 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2006 | 154 | 0.010 |
Why?
|
| Developmental Disabilities | 1 | 2011 | 771 | 0.010 |
Why?
|
| Sleep Deprivation | 1 | 2005 | 45 | 0.010 |
Why?
|
| Psychological Tests | 1 | 2005 | 87 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 946 | 0.010 |
Why?
|
| Fatigue | 1 | 2005 | 195 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 306 | 0.010 |
Why?
|
| Israel | 1 | 2004 | 48 | 0.010 |
Why?
|
| History, Ancient | 1 | 2004 | 53 | 0.010 |
Why?
|
| Gastric Mucosa | 1 | 2007 | 493 | 0.010 |
Why?
|
| Jews | 1 | 2004 | 34 | 0.010 |
Why?
|
| Life Style | 1 | 2007 | 447 | 0.010 |
Why?
|
| Respiratory Tract Diseases | 1 | 2004 | 83 | 0.010 |
Why?
|
| Memory Disorders | 1 | 2005 | 203 | 0.010 |
Why?
|
| Infant | 2 | 2011 | 13321 | 0.010 |
Why?
|
| Inflammation | 1 | 2010 | 1490 | 0.010 |
Why?
|
| Contrast Media | 1 | 2006 | 493 | 0.010 |
Why?
|
| Peptic Ulcer Perforation | 1 | 2002 | 14 | 0.010 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 2002 | 19 | 0.010 |
Why?
|
| Misoprostol | 1 | 2002 | 24 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2011 | 15011 | 0.010 |
Why?
|
| Research Design | 1 | 2006 | 718 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2002 | 177 | 0.010 |
Why?
|
| Radiography | 1 | 2003 | 739 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2005 | 1232 | 0.010 |
Why?
|
| Alcoholism | 1 | 2002 | 244 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 2004 | 472 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2002 | 544 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2002 | 401 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 2002 | 482 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 1896 | 0.010 |
Why?
|
| Quality of Life | 1 | 2005 | 2089 | 0.010 |
Why?
|